Browse drugs

…ive analysis of 210 SLE patients treated between 2000-2022 with rituximab. Super-responders were defined by: (1) at least 3 years of foll…

…Objectives Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble…

…tment platelet reactivity to prasugrel, even after doubling the prasugrel dose. This case highlights rare resistance to newer P2Y12 inhib…

…own to be consistent across multiple hospital sites.Conclusions SGLT2 inhibitors are associated with a reduced risk of dementia and AD compared …

…ory values. The patient was then discharged on a stable dose of ruxolitinib, anakinra and prednisone. This case illustrates the therapeutic…

…1, GLI1) signalling pathways were also significantly altered by ascorbate treatment. Interestingly, many DEGs have no currently assigned …

…P concentrations but does not attenuate the prognostic value of NT-proBNP. Lowering guideline-recommended NT-proBNP thresholds for obese …

…all-cause mortality occurred in 551 out of 13,239 (4.2%) in the empagliflozin group and 6,589 out of 49,264 (13.4%) in the active control gro…

… but were attenuated in intention-to-treat analyses.Conclusions Clozapine initiators had an elevated risk of neutropenia-related hospital…

…ng is suspected. If wheeze is detected, an inhaled short-acting β 2-agonist is administered and WheezeScan determines if wheeze resolves th…

…dings remained after adjusting for important confounders. Given metformin’s anti-ageing therapeutic effects, the reduction in risk is pla…

…oritized biological activity over toxicity thresholds. Although feladilimab demonstrated favorable safety and robust receptor occupancy, cl…